Elan in €45m deal with British biotech firm

Pharmaceutical giant Elan is to receive $55m (€45.07m) from British biotech firm Vernalis for the North American commericialisation rights to migraine treatment Frova.

Elan in €45m deal  with British biotech firm

Pharmaceutical giant Elan is to receive $55m (€45.07m) from British biotech firm Vernalis for the North American commericialisation rights to migraine treatment Frova.

Vernalis, formed from a merger of RiboTargets and Vernalis Group, changed its name to Vernalis in 2003.

Already a subscriber? Sign in

You have reached your article limit.

Unlimited access. Half the price.

Annual €120 €60

Best value

Monthly €10€5 / month

More in this section

The Business Hub

Newsletter

News and analysis on business, money and jobs from Munster and beyond by our expert team of business writers.

Cookie Policy Privacy Policy Brand Safety FAQ Help Contact Us Terms and Conditions

© Examiner Echo Group Limited